Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

FDG and NaF PET/CT Imaging Prognostic for OS in Metastatic GU Cancers Treated With Cabozantinib/Nivolumab Combos

February 18th 2022

Fluorodeoxyglucose PET/CT and sodium fluoride PET/CT baseline functional imaging parameters and percent change in lesion number observed on follow-up imaging was linked with overall survival and found to be prognostic in patients with metastatic genitourinary cancers.

Dr. Munver on the Utilization of Mitomycin Gel in GU Cancers

February 14th 2022

Ravi Munver, MD, discusses the utilization of mitomycin gel in genitourinary cancers.

Metastatic Urothelial Carcinoma: Optimizing Use of Frontline Maintenance Therapy

February 9th 2022

Shared insight on the use of maintenance therapy in metastatic urothelial carcinoma with regard to PD-L1 testing and patient education.

Interpreting JAVELIN Bladder 100: Avelumab in Metastatic Urothelial Carcinoma

February 9th 2022

Ignacio Duran, MD, PhD, reflects on the JAVELIN Bladder 100 trial, which analyzed avelumab as frontline maintenance therapy in metastatic urothelial carcinoma.

Immunotherapy’s Roles in Treating Metastatic Urothelial Carcinoma

February 2nd 2022

Considerations for the role of immunotherapy in metastatic urothelial carcinoma as maintenance or switch therapy.

A Global View on Metastatic Urothelial Carcinoma

February 2nd 2022

Expert perspective on the current treatment paradigm of metastatic urothelial carcinoma across different regions of the world.

Nivolumab/Cabozantinib Combo Improves Patient-Reported Outcomes Over Sunitinib in RCC

January 26th 2022

The combination of nivolumab and cabozantinib was associated with improved quality of life compared with sunitinib in patients with previously untreated advanced renal cell carcinoma, according to patient-reported outcome data from the phase 3 CheckMate-9ER trial.

Long-Term Data Confirm Benefit of Erdafitinib in FGFR-Mutated Urothelial Carcinoma

January 25th 2022

The FGFR TKI erdafitinib continued to provide consistent clinical benefits with a manageable safety profile when used in the second-line treatment of patients with locally advanced or metastatic urothelial carcinoma harboring FGFR alterations.

Dr. Galsky on Clinical Trials That Addressed Key Questions in Urothelial Cancer

January 24th 2022

Matthew Galsky, MD, discusses clinical trials that addressed key questions in urothelial cancer.

Nivolumab/Ipilimumab Showcases Prolonged Treatment-Free Survival in Advanced RCC

January 24th 2022

Over a 42-month period, the combination of nivolumab and ipilimumab induced a longer treatment-free survival compared with sunitinib (Sutent) when used as frontline therapy in patients with advanced renal cell carcinoma.

Dr. Bakouny on Understanding the Biology of Translocation RCC

January 19th 2022

Ziad Bakouny, MD, MSc, discusses understanding the biology of translocation renal cell carcinoma.

Dr. Yentz on Translating Data to Real-World Clinical Practice in RCC

January 18th 2022

Sarah Elizabeth Yentz, MD, discusses translating data to real-world clinical practice in renal cell carcinoma.

Nectin-4 Emerges as a Therapeutic Target in Urothelial Carcinoma and Beyond

January 2nd 2022

Most ongoing clinical trials exploring nectin-4 as a target involve studies of enfortumab vedotin and its potential synergy with immune checkpoint inhibitors in bladder cancer, while several other early-phase studies are testing novel agents in solid tumors.

Dr. Galsky the Evolution of Standard Options in Urothelial Carcinoma

December 23rd 2021

Matthew Galsky, MD, discusses the evolution of standard of care treatment options in urothelial carcinoma.

FDA Approval Sought for Dovitinib for Third-Line Renal Cell Carcinoma

December 22nd 2021

A new drug application has been submitted to the FDA seeking the marketing approval of dovitinib as a potential option in the third-line treatment of patients with renal cell carcinoma.

EU Panel Recommends Adjuvant Pembrolizumab for Select RCC Following Surgery

December 17th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of single-agent pembrolizumab for use as an adjuvant treatment in adult patients with renal cell carcinoma who are at increased risk of recurrence after nephrectomy, or following nephrectomy and the resection of metastatic lesions.

Enfortumab Vedotin Approaches EU Approval for Locally Advanced or Metastatic Urothelial Cancer

December 17th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion in favor of the approval of enfortumab vedotin as a monotherapy in the treatment of adult patients with locally advanced or metastatic urothelial cancer.

Pembrolizumab Proves Potential as New Standard of Care for RCC in Adjuvant Setting

December 17th 2021

Pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs placebo as a postnephrectomy adjuvant therapy in patients with renal cell carcinoma at intermediate-high or high risk of recurrence, and in those who are M1 with no evidence of disease.

FDA Approval Insights: Adjuvant Pembrolizumab in RCC

December 6th 2021

Dr. Choueiri discusses the significance of the FDA approval of pembrolizumab as adjuvant therapy in renal cell carcinoma and key data from the pivotal phase 3 KEYNOTE-564 trial.

Pembrolizumab/Axitinib Improves Outcomes in Japanese mRCC Subgroup

November 30th 2021

The combination of pembrolizumab and axitinib demonstrated comparable activity and safety vs sunitinib in Japanese patients vs the global population of patients with newly diagnosed metastatic renal cell carcinoma enrolled in the phase 3 KEYNOTE-426 trial.